| Dr Atabak Asvadi Kermani, MD | |
|
200 Hawkins Dr, Iowa City, IA 52242-1009 | |
| (319) 384-7560 | |
| (614) 412-2685 |
| Full Name | Dr Atabak Asvadi Kermani |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 200 Hawkins Dr, Iowa City, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407383870 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R-10821 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Miami County Medical Center | Paola, KS | Hospital |
| Wright Memorial Hospital | Trenton, MO | Hospital |
| Van Buren County Hospital | Keosauqua, IA | Hospital |
| Saint John Hospital | Leavenworth, KS | Hospital |
| Pershing Memorial Hospital | Brookfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Van Buren County Hospital | 7214829530 | 25 |
| Stanley Mathew, Md Pllc | 8729128384 | 10 |
| General John J Pershing Memorial Hospital Association | 2860306750 | 19 |
| Miami County Medical Center Inc | 2163311457 | 21 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | St Anthony Regional Hospital And Nursing Home |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891711925 PECOS PAC ID: 4688586829 Enrollment ID: O20031105000218 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Pocahontas Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609989581 PECOS PAC ID: 7012820012 Enrollment ID: O20031106000417 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Stewart Memorial Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285652909 PECOS PAC ID: 4486563707 Enrollment ID: O20031107000249 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Knoxville Community Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770591661 PECOS PAC ID: 6608787056 Enrollment ID: O20031119000804 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Jefferson County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881294536 PECOS PAC ID: 9335059575 Enrollment ID: O20031223000606 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Fort Madison Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083764393 PECOS PAC ID: 8729971841 Enrollment ID: O20040203001066 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Humboldt County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043395247 PECOS PAC ID: 8921997867 Enrollment ID: O20040310001518 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Van Buren County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316063076 PECOS PAC ID: 7214829530 Enrollment ID: O20040329001814 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Ida County Iowa Community Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1265461180 PECOS PAC ID: 9537070826 Enrollment ID: O20061104000191 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Iowa Emergency Physicians Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386879427 PECOS PAC ID: 5991856064 Enrollment ID: O20090701000057 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Entity Name | Stanley Mathew, Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720312465 PECOS PAC ID: 8729128384 Enrollment ID: O20091214000186 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Atabak Asvadi Kermani, MD 1201 3rd Ave Se, Cedar Rapids, IA 52403-4009 Ph: (319) 730-7300 | Dr Atabak Asvadi Kermani, MD 200 Hawkins Dr, Iowa City, IA 52242-1009 Ph: (319) 384-7560 |
News Archive
Researchers recently reviewed current knowledge on links between autophagy and coronaviruses and how this knowledge can be used to repurpose autophagy modulators as potential treatment options for COVID-19. The review is published in the journal Frontiers in Microbiology.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.
Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted European Patent 1749836 covering the use of VEGF-D protein and antibodies to VEGF-D in a broad spectrum of therapeutic indications, including the treatment of cancer.
In a first-of-its-kind study, Mount Sinai researchers have discovered a novel technique to monitor laryngeal and vagus nerve function while patients are under anesthesia during otolaryngology and neurosurgery procedures.
› Verified 6 days ago
Joshua Craig Borwick, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-384-7507 | |
Kaylie Duit, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-384-7222 Fax: 319-384-7822 | |
Adelaide M Gurwell, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-1616 | |
Mr. Nathan Alan Shaw, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-384-7000 | |
Alexander Young-oo Dresden, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-384-7222 Fax: 319-384-7822 | |
Dr. Maresi Berry-stoelzle, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3640 Middlebury Rd, Iowa City, IA 52245 Phone: 319-384-7000 Fax: 319-467-7400 | |
Michael Maharry, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-384-7222 Fax: 319-384-7822 |